関係書目

ウィキペディア小見出し辞書

関係書目

出典: フリー百科事典『ウィキペディア（Wikipedia）』 (2021/08/27 01:41 UTC 版)

「結核の管理」の記事における「関係書目」の解説

^ a b Sterling T. R., Villarino M. E., Borisov, Chaisson R. E. (2011). “Three months of rifapentine and isoniazid for latent tuberculosis infection”. New England Journal of Medicine 365 (23): 2155?2166. doi:10.1056/nejmoa1104875. PMID 22150035. ^ a b World Health Organization. Guidelines on the management of latent tuberculosis infection. WHO/HTM/TB/2015.01. Geneva: World Health Organization; 2015. ^ a) ftp://ftp.cdc.gov/pub/nchstp/tb/...web/.../3.0%20Drug%20Resistance.ppt,b[リンク切れ]) http://harrisons.unboundmedicine.com/harrisons/ub/view/Harrisons-Manual-of-Medicine/148139/all/Antituberculosis_Treatment_Regimens_%5Btable%5D ^ Multidrug and extensively drug-resistant TB (M/XDR-TB) Drugs Used in the Treatment of Tuberculosis ^ “Streptomycin Treatment of Pulmonary Tuberculosis: A Medical Research Council Investigation”. British Medical Journal 2 (4582): 769?82. (October 1948). doi:10.1136/bmj.2.4582.769. PMC 2091872. PMID 18890300. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2091872/. ^ “Empirical treatment with a fluoroquinolone delays the treatment for tuberculosis and is associated with a poor prognosis in endemic areas”. Thorax 61 (10): 903?08. (October 2006). doi:10.1136/thx.2005.056887. PMC 2104756. PMID 16809417. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2104756/. ^ David HL (November 1970). “Probability Distribution of Drug-Resistant Mutants in Unselected Populations of Mycobacterium tuberculosis”. Applied Microbiology 20 (5): 810?14. PMC 377053. PMID 4991927. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC377053/. ^ British Thoracic Society (October 1984). “A controlled trial of 6 months' chemotherapy in pulmonary tuberculosis. Final report: results during the 36 months after the end of chemotherapy and beyond.”. British Journal of Diseases of the Chest 78 (4): 330?36. doi:10.1016/0007-0971(84)90165-7. PMID 6386028. ^ Ormerod LP, Horsfield N; Horsfield (July 1987). “Short-course antituberculous chemotherapy for pulmonary and pleural disease: 5 years' experience in clinical practice”. British Journal of Diseases of the Chest 81 (3): 268?71. doi:10.1016/0007-0971(87)90160-4. PMID 3663498. ^ East AFrican/British Medical Research Councils (1986). “Controlled clinical trial of 4 short-course regimens of chemotherapy (three 6-month and one 8-month) for pulmonary tuberculosis: final report. East and Central African/British Medical Research Council Fifth Collaborative Study”. Tubercle 67 (1): 5–15. PMID 3521015. ^ a b c Elzinga G, Raviglione MC, Maher D; Raviglione; Maher (March 2004). “Scale up: meeting targets in global tuberculosis control”. Lancet 363 (9411): 814?19. doi:10.1016/S0140-6736(04)15698-5. PMID 15016493. ^ Cohn DL, Catlin BJ, Peterson KL, Judson FN, Sbarbaro JA; Catlin; Peterson; Judson; Sbarbaro (March 1990). “A 62-dose, 6-month therapy for pulmonary and extrapulmonary tuberculosis. A twice-weekly, directly observed, and cost-effective regimen”. Annals of Internal Medicine 112 (6): 407?15. doi:10.7326/0003-4819-76-3-112-6-407. PMID 2106816. ^ a b Dye C, Watt CJ, Bleed DM, Williams BG; Watt; Bleed; Williams (2003). “What is the limit to case detection under the DOTS strategy for tuberculosis control?”. Tuberculosis 83 (1?3): 35?43. doi:10.1016/S1472-9792(02)00056-2. PMID 12758187. ^ Grange JM; Zumla A (June 2002). “The global emergency of tuberculosis: what is the cause?”. The Journal of the Royal Society for the Promotion of Health 122 (2): 78?81. doi:10.1177/146642400212200206. PMID 12134771. ^ Harries AD, Jahn A, Zachariah R, Enarson D; Jahn; Zachariah; Enarson (June 2008). “Adapting the DOTS framework for tuberculosis control to the management of non-communicable diseases in sub-Saharan Africa”. PLoS Medicine 5 (6): e124. doi:10.1371/journal.pmed.0050124. PMC 3280072. PMID 18547138. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3280072/. ^ Iseman MD (November 1998). “MDR-TB and the developing world--a problem no longer to be ignored: the WHO announces 'DOTS Plus' strategy”. The International Journal of Tuberculosis and Lung Disease 2 (11): 867. PMID 9848604. http://openurl.ingenta.com/content/nlm?genre=article&issn=1027-3719&volume=2&issue=11&spage=867&aulast=Iseman. ^ Sterling TR, Lehmann HP, Frieden TR; Lehmann; Frieden (March 2003). “Impact of DOTS compared with DOTS-plus on multidrug resistant tuberculosis and tuberculosis deaths: decision analysis”. BMJ 326 (7389): 574. doi:10.1136/bmj.326.7389.574. PMC 151519. PMID 12637401. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC151519/. ^ Campbell IA, Ormerod LP, Friend JA, Jenkins PA, Prescott RJ; Ormerod; Friend; Jenkins; Prescott (November 1993). “Six months versus nine months chemotherapy for tuberculosis of lymph nodes: final results”. Respiratory Medicine 87 (8): 621?23. doi:10.1016/S0954-6111(05)80265-3. PMID 8290746. ^ Upadhyay SS, Saji MJ, Yau AC; Saji; Yau (August 1996). “Duration of antituberculosis chemotherapy in conjunction with radical surgery in the management of spinal tuberculosis”. Spine 21 (16): 1898?903. doi:10.1097/00007632-199608150-00014. PMID 8875723. ^ Darbyshire, J.; Darbyshire, J (1999). “Five-year assessment of controlled trials of short-course chemotherapy regimens of 6, 9 or 18 months' duration for spinal tuberculosis in patients ambulatory from the start or undergoing radical surgery. Fourteenth report of the Medical Research Council Working Party on Tuberculosis of the Spine”. International Orthopaedics 23 (2): 73?81. doi:10.1007/s002640050311. PMC 3619789. PMID 10422019. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3619789/. ^ Parthasarathy R, Sriram K, Santha T, Prabhakar R, Somasundaram PR, Sivasubramanian S; Sriram; Santha; Prabhakar; Somasundaram; Sivasubramanian (May 1999). [http://bjj.boneandjoint.org.uk/content/81-B/3/464 “Short-course chemtherapy for tuberculosis of the spine. A comparison between ambulant treatment and radical surgery--ten-year report”]. The Journal of Bone and Joint Surgery. British Volume 81-B (3): 464?71. PMID 10872368. http://bjj.boneandjoint.org.uk/content/81-B/3/464. ^ “Tuberculous Meningitis: A 30-Year Review”. Clin Infect Dis 17 (6): 987–94. (1993). doi:10.1093/clinids/17.6.987. PMID 8110957. ^ “Polymorphonuclear pleocytosis in the cerebrospinal fluid during chemotherapy for tuberculous meningitis”. J Neurol 233 (4): 237?41. (1986). doi:10.1007/BF00314027. PMID 3746363. ^ “Central nervous system tuberculosis after resolution of miliary tuberculosis”. Pediatr Infect Dis J 17 (6): 519?23. (1998). doi:10.1097/00006454-199806000-00019. PMID 9655548. ^ Misra, U.K.; Kalita, J.; Nair, P.P. (2010). “Role of aspirin in tuberculous meningitis: a randomized open-label placebo-controlled trial”. J Neurol Sci 293: 12–17. doi:10.1016/j.jns.2010.03.025. ^ “Tuberculous meningitis: take an aspirin and call me in the morning?”. Clin Infect Dis 51 (12): iv. (2010). doi:10.1086/657238. ^ “Dexamethasone for the treatment of tuberculous meningitis in adolescents and adults”. N Engl J Med 351 (17): 1741–51. (2004). doi:10.1056/NEJMoa040573. PMID 15496623. ^ “Novel adjunctive therapies for the treatment of tuberculosis”. Current Molecular Medicine 14 (3): 285–395. (2014). doi:10.2174/1566524013666131118112431. PMC 4484774. PMID 24236454. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4484774/. ^ “The use of thalidomide in the treatment of intracranial tuberculomas in adults: two case reports”. J Infect 47 (3): 251–55. (2003). doi:10.1016/S0163-4453(03)00077-X. PMID 12963389. ^ “Dietary constituents and rifampicin absorption”. Tubercle 68 (2): 151?52. (June 1987). doi:10.1016/0041-3879(87)90034-1. PMID 3660467. ^ “Pharmacokinetics of rifampin under fasting conditions, with food, and with antacids”. Chest 115 (1): 12?18. (January 1999). doi:10.1378/chest.115.1.12. PMID 9925057. ^ “Effect of meals on rifampicin absorption”. Lancet 2 (7874): 197?98. (July 1974). doi:10.1016/S0140-6736(74)91487-1. PMID 4135611. ^ “Pharmacokinetics of isoniazid under fasting conditions, with food, and with antacids”. The International Journal of Tuberculosis and Lung Disease 3 (8): 703?10. (August 1999). PMID 10460103. http://openurl.ingenta.com/content/nlm?genre=article&issn=1027-3719&volume=3&issue=8&spage=703&aulast=Peloquin. ^ “Food reduces isoniazid bioavailability in normal volunteers”. The Journal of the Association of Physicians of India 39 (6): 470?71. (June 1991). PMID 1938852. ^ “Study of the effect of concomitant food on the bioavailability of rifampicin, isoniazid and pyrazinamide”. Tubercle and Lung Disease 76 (2): 109?13. (April 1995). doi:10.1016/0962-8479(95)90551-0. PMID 7780091. ^ “Pharmacokinetics of pyrazinamide under fasting conditions, with food, and with antacids”. Pharmacotherapy 18 (6): 1205?11. (1998). doi:10.1002/j.1875-9114.1998.tb03138.x. PMID 9855317. ^ “Pharmacokinetics of Ethambutol under Fasting Conditions, with Food, and with Antacids”. Antimicrobial Agents and Chemotherapy 43 (3): 568?72. (March 1999). PMC 89161. PMID 10049268. http://aac.asm.org/cgi/pmidlookup?view=long&pmid=10049268. ^ http://www.iblogscience.com/incidence-of-extrapulmonary-tb-trending-upward-2/ ^ Gallardo, CR; Rigau Comas, D; Valderrama Rodriguez, A; Roque I Figuls, M; Parker, LA; Cayla, J; Bonfill Cosp, X (17 May 2016). “Fixed-dose combinations of drugs versus single-drug formulations for treating pulmonary tuberculosis.”. The Cochrane Database of Systematic Reviews 5: CD009913. doi:10.1002/14651858.CD009913.pub2. PMC 4916937. PMID 27186634. http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD009913.pub2/full 2016年6月6日閲覧。. ^ “Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis”. American Journal of Respiratory and Critical Care Medicine 167 (11): 1472?77. (June 2003). doi:10.1164/rccm.200206-626OC. PMID 12569078. ^ “Adverse reactions to first-line antituberculosis drugs”. Expert Opinion on Drug Safety 5 (2): 231?49. (March 2006). doi:10.1517/14740338.5.2.231. PMID 16503745. ^ “Toxic hepatitis with isoniazid and rifampin. A meta-analysis”. Chest 99 (2): 465?71. (February 1991). doi:10.1378/chest.99.2.465. PMID 1824929. ^ Namasivayam, Sivaranjani (2017). “Longitudinal profiling reveals a persistent intestinal dysbiosis triggered by conventional anti-tuberculosis therapy”. Microbiome 5 (71). doi:10.1186/s40168-017-0286-2. PMC 5501520. PMID 28683818. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5501520/. ^ Wipperman, Matthew (2017). “Antibiotic treatment for Tuberculosis induces a profound dysbiosis of the microbiome that persists long after therapy is completed.”. Scientific Reports 7 (1): 10767. doi:10.1038/s41598-017-10346-6. PMC 5589918. PMID 28883399. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5589918/. ^ Hong Kong Chest Service Tuberculosis Research Centre, British Medical Research Council. (1989). “A controlleed trial of 3-month, 4-month, and 6-month regimens of chemotherapy for sputum smear-negative pulmonary tuberculosis: results at 5 years”. Am Rev Respir Dis 139 (4): 871–76. doi:10.1164/ajrccm/139.4.871. ^ a b “Tuberculosis in the UK: Annual report on tuberculosis surveillance in the UK 2010”. London: Tuberculosis Section, Health Protection Agency Centre for Infections (2010年11月). 2011年7月1日時点のオリジナルよりアーカイブ。2011年7月4日閲覧。 ^ Dheda, Keertan, ed (2008). “Rapid Molecular Detection of Rifampicin Resistance Facilitates Early Diagnosis and Treatment of Multi-Drug Resistant Tuberculosis: Case Control Study”. PLoS ONE 3 (9): e3173. doi:10.1371/journal.pone.0003173. PMC 2526158. PMID 18779863. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2526158/. ^ British Thoracic Association (1982). “A controlled trial of six months chemotherapy in pulmonary tuberculosis. Second report: results during the 24 months after the end of chemotherapy. British Thoracic Association”. Am Rev Respir Dis 126 (3): 460–2. doi:10.1164/arrd.1982.126.3.460. PMID 6751175. ^ a b British Thoracic Society (1984). “A controlled trial of 6 months' chemotherapy in pulmonary tuberculosis. Final report: results during the 36 months after the end of chemotherapy and beyond. British Thoracic Society”. Br J Dis Chest 78 (4): 330–336. doi:10.1016/0007-0971(84)90165-7. PMID 6386028. ^ British Thoracic Society (1988). “Short course chemotherapy for lymph node tuberculosis: final report at 5 years. British Thoracic Society Research Committee”. Br J Dis Chest 82 (3): 282–4. PMID 3073808. ^ a b “The results of 9-month isoniazid-rifampin therapy for pulmonary tuberculosis under program conditions in San Francisco”. Am Rev Respir Dis 138 (6): 1622–4. (1988). doi:10.1164/ajrccm/138.6.1622. ^ American Thoracic Society/Centers for Disease Control and Prevention (1994). “Treatment of tuberculosis and tuberculosis infection in adults and children.”. Am J Respir Crit Care Med 149 (5): 1359–74. doi:10.1164/ajrccm.149.5.8173779. PMID 8173779. ^ American Thoracic Society/Centers for Disease Control/Infectious Diseases Society of America (2003). “Treatment of tuberculosis.”. MMWR. Recommendations and Reports : Morbidity and Mortality Weekly Report. Recommendations and Reports 52 (RR-11): 1–77. PMID 12836625. ^ Combs DL; O'Brien RJ; Geiter LJ (1990). “USPHS Tuberculosis Short-Course Chemotherapy Trial 21: effectiveness, toxicity, and acceptability. The report of final results”. Ann Int Med 112 (6): 397–406. doi:10.7326/0003-4819-76-3-112-6-397. PMID 2155569. http://annals.org/article.aspx?articleid=703742. ^ 妊娠および分娩によってもたらされた母体や生殖器の変化が、分娩の終了（医学的には分娩第3期、いわゆる後産期終了）から妊娠前の状態に戻るまでの期間のこと。 ^ “Treatment of Multidrug-Resistant Tuberculosis during Pregnancy: Long-Term Follow-Up of 6 Children with Intrauterine Exposure to Second-Line Agents”. Clin Infect Dis 40 (11): 1689?92. (2005). doi:10.1086/430066. PMID 15889370. https://academic.oup.com/cid/article/40/11/1689/447698. ^ “Drug‐resistant tuberculosis and pregnancy: Treatment outcomes of 38 cases in Lima, Peru”. Clin Infect Dis 48 (10): 1413–19. (2009). doi:10.1086/598191. PMC 4824949. PMID 19361302. https://academic.oup.com/cid/article/48/10/1413/423232. ^ GFRとは糸球体濾過量の略で、フィルターの役目を果たす糸球体が1分間にどれくらいの血液を濾過し、尿をつくれるかを表す。 ^ “Virological response to highly active antiretroviral therapy is unaffected by antituberculosis therapy”. J Infect Dis 193 (10): 1437–40. (2006). doi:10.1086/503437. PMID 16619192. ^ Jenny‐Avital1 ER, Joseph K (2009). “Rifamycin‐resistant Mycobacterium tuberculosis in the highly active antiretroviral therapy era: A report of 3 relapses with acquired rifampin resistance following alternate‐day rifabutin and boosted protease inhibitor therapy”. Clin Infect Dis 48 (10): 1471–74. doi:10.1086/598336. PMID 19368504. https://academic.oup.com/cid/article/48/10/1471/425080. ^ “Severe cutaneous hypersensitivity reactions during treatment of tuberculosis in patients with HIV infection in Tanzania”. Trop Geogr Med 44 (4): 308–11. (1992). PMID 1284179. ^ “HIV seroprevalence rate and incidence of adverse skin reactions in adults with pulmonary tuberculosis receiving thiacetazone free anti-tuberculosis treatment in Yaounde, Cameroon”. East Afr Med J 74 (8): 474–77. (1997). PMID 9487410. ^ World Health Organisation. “WHO Global Task Force outlines measures to combat XDR-TB worldwide”. 2006年10月21日閲覧。 ^ a b Centers for Disease Control and Prevention (2006). “Emergence of Mycobacterium tuberculosis with Extensive Resistance to Second-Line Drugs — Worldwide, 2000–2004”. MMWR Weekly 55 (11): 301–05. https://www.cdc.gov/mmwr/preview/mmwrhtml/mm5511a2.htm. ^ a b Sarah McGregor. “New TB strain could fuel South Africa AIDS toll”. Reuters. 2006年9月17日閲覧。[リンク切れ] ^ “The emergence of drug-resistant tuberculosis in New York City”. N Engl J Med 328 (8): 521–56. (1993). doi:10.1056/NEJM199302253280801. PMID 8381207. ^ Laurie Garrett (2000). Betrayal of trust: the collapse of global public health. New York: Hyperion. p. 268ff. ISBN 9780786884407 ^ a b Farmer Paul (2001). “The Major Infectious Diseases in the World -- To Treat or Not to Treat?”. N Engl J Med 345 (3): 208?210. doi:10.1056/nejm200107193450310. PMID 11463018. ^ “Extensively drug-resistant tuberculosis in a young child after travel to India”. The Lancet Infectious Diseases 15 (12): 1485?1491. (2015). doi:10.1016/S1473-3099(15)00356-4. PMC 4843989. PMID 26607130. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4843989/. ^ “Extreme drug resistance in tuberculosis (XDR-TB): global survey of supranational reference laboratories for _Mycobacterium tuberculosis_ with resistance to second-line drugs”. Int J Tuberc Lung Dis 9 (Suppl 1): S77. (2005). ^ Centers for Disease Control and Prevention (2006). “Emergence of Mycobacterium tuberculosis with Extensive Resistance to Second-Line Drugs — Worldwide, 2000–2004”. MMWR Weekly 55 (11): 301–05. https://www.cdc.gov/mmwr/preview/mmwrhtml/mm5611a3.htm?s_cid=mm5611a3_e. ^ “Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa”. Lancet 368 (9547): 1575–80. (2006). doi:10.1016/S0140-6736(06)69573-1. PMID 17084757. ^ Angela Quintal. “314 XDR-TB cases reported in SA”. Cape Times. 2007年4月4日閲覧。[リンク切れ] ^ “Extensively Drug-resistant Tuberculosis, Italy and Germany”. Emerging Infectious Diseases 13 (5): 780?82. (2007). doi:10.3201/eid1305.070200. PMC 2738462. PMID 18044040. https://www.cdc.gov/EID/content/13/5/07-0200.htm. ^ News24. “300+ cases of killer TB in SA”. 2007年10月1日時点のオリジナルよりアーカイブ。2006年11月23日閲覧。 ^ “XDR-TB in South Africa: No Time for Denial or Complacency”. PLoS Med 4 (1): e50. (2007). doi:10.1371/journal.pmed.0040050. PMC 1779818. PMID 17253901. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1779818/. ^ “Treatment outcomes among patients with multidrug-resistant tuberculosis: systematic review and meta-analysis”. Lancet Infect Dis 9 (3): 153?61. (2009). doi:10.1016/S1473-3099(09)70041-6. PMID 19246019. ^ “Community-based therapy for multidrug-resistant tuberculosis in Lima, Peru”. N Engl J Med 348 (2): 119?28. (2003). doi:10.1056/NEJMoa022928. PMID 12519922. http://content.nejm.org/cgi/content/abstract/348/2/119. ^ Gillespie SH (2002). “Evolution of drug resistance in Mycobacterium tuberculosis: clinical and molecular perspective”. Antimicrob Agents Chemother 46 (2): 267–74. doi:10.1128/AAC.46.2.267-274.2002. PMC 127054. PMID 11796329. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC127054/. ^ “Rapid Genotypic Detection of Rifampin- and Isoniazid-Resistant Mycobacterium tuberculosis Directly in Clinical Specimens”. J Clin Microbiol 44 (7): 2605?08. (2006). doi:10.1128/JCM.00752-06. PMC 1489488. PMID 16825393. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1489488/. ^ “Molecular characterization of isoniazid and rifampin resistance of Mycobacterium tuberculosis clinical isolates from Malatya, Turkey”. Microbial Drug Resistance 11 (2): 94–99. (2005). doi:10.1089/mdr.2005.11.94. PMID 15910221. ^ Steering Group; Ernesto Jaramillo... (2008). Guidelines for the programmatic management of drug-resistant tuberculosis: emergency update 2008 (WHO/HTM/TB/2008.402). Geneva, Switzerland: World Health Organization. p. 51. ISBN 9789241547581 ^ Reljic R (2007). “IFN-gamma therapy of tuberculosis and related infections”. J Interferon Cytokine Res 27 (5): 353–64. doi:10.1089/jir.2006.0103. PMID 17523867. ^ “Old drug combination in TB fight”. BBC News. (2009年2月27日). http://news.bbc.co.uk/2/hi/health/7913190.stm 2009年2月27日閲覧。 ^ “Meropenem/Clavulanate and Linezolid Treatment for Extensively Drug-Resistant Tuberculosis”. Pediatric Infectious Disease Journal 30 (9): 812?3. (2011). doi:10.1097/INF.0b013e3182154b05. PMID 21378593. ^ Ziganshina, Lilia E; Squire, Stephen B (2008). “Fluoroquinolones for treating tuberculosis”. Cochrane Database of Systematic Reviews (1): CD004795. doi:10.1002/14651858.CD004795.pub3. PMID 18254061. ^ “Clinical outcome of individualised treatment of multidrug-resistant tuberculosis in Latvia: a retrospective cohort study”. Lancet 365 (9456): 318?26. (2005). doi:10.1016/S0140-6736(05)17786-1. PMID 15664227. http://linkinghub.elsevier.com/retrieve/pii/S0140673605177861. ^ “Arginine as an adjuvant to chemotherapy improves clinical outcome in active tuberculosis”. Eur Respir J 21 (3): 483–88. (2003). doi:10.1183/09031936.03.00090702. PMID 12662006. http://erj.ersjournals.com/cgi/content/abstract/21/3/483. ^ a b “1,25-Dihydroxyvitamin D3 Induces Nitric Oxide Synthase and Suppresses Growth of Mycobacterium tuberculosis in a Human Macrophage-Like Cell Line”. Infection and Immunity 66 (11): 5314–21. (November 1, 1998). PMC 108664. PMID 9784538. http://iai.asm.org/cgi/content/abstract/66/11/5314. ^ “Imipenem for Treatment of Tuberculosis in Mice and Humans”. Antimicrob Agents Chemother 49 (7): 2816–21. (2005). doi:10.1128/AAC.49.7.2816-2821.2005. PMC 1168716. PMID 15980354. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1168716/. ^ “Activity of amoxicillin/clavulanate in patients with tuberculosis”. Clin Infect Dis 26 (4): 874–77. (1998). doi:10.1086/513945. PMID 9564467. ^ “Early bactericidal activity of amoxicillin in combination with clavulanic acid in patients with sputum smear-positive pulmonary tuberculosis”. Scand J Infect Dis 33 (6): 466–69. (2001). doi:10.1080/00365540152029954. PMID 11450868. ^ “Chemotherapeutic activity of clofazimine and its analogues against Mycobacterium tuberculosis. In vitro, intracellular, and in vivo studies”. Am J Respir Crit Care Med 151 (4): 1083–86. (April 1, 1995). doi:10.1164/ajrccm.151.4.7697235. PMID 7697235. http://ajrccm.atsjournals.org/cgi/content/abstract/151/4/1083. ^ “Effective Treatment of Acute and Chronic Murine Tuberculosis with Liposome-Encapsulated Clofazimine” (PDF). Antimicrob Agents Chemother 43 (7): 1638–43. (1999). PMC 89336. PMID 10390215. http://aac.asm.org/cgi/reprint/43/7/1638.pdf. ^ Janulionis, E.; Sofer, C; Song, HY; Wallis, RS (2004). [http://aac.asm.org/cgi/reprint/48/8/3133.pdf “Lack of Activity of Orally Administered Clofazimine against Intracellular Mycobacterium tuberculosis in Whole-Blood Culture”] (PDF). Antimicrob Agents Chemother 48 (8): 3133–35. doi:10.1128/AAC.48.8.3133-3135.2004. PMC 478499. PMID 15273133. http://aac.asm.org/cgi/reprint/48/8/3133.pdf. ^ Shubin H; Sherson J; Pennes E; Glaskin A; Sokmensuer A. (1958). “Prochlorperazine (compazine) as an aid in the treatment of pulmonary tuberculosis”. Antibiotic Med Clin Ther. 5 (5): 305–09. PMID 13521769. ^ “Metronidazole is bactericidal to dormant cells of Mycobacterium tuberculosis”. Antimicrob Agents Chemother 38 (9): 2054–58. (1994). doi:10.1128/AAC.38.9.2054. PMC 284683. PMID 7811018. http://aac.asm.org/cgi/content/abstract/38/9/2054. ^ “FDA Press Release”. U.S. Food and Drug Administration (2012年12月31日). 2013年1月3日閲覧。 ^ Carroll, John (2012年12月31日). “J&J wins accelerated OK for first new TB drug in 40 years”. fiercebiotech.com. 2013年1月3日閲覧。 ^ “A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis”. Nature 405 (6789): 962–66. (2000). doi:10.1038/35016103. PMID 10879539. ^ a b c Anurag Bhargava; Lancelot Pinto; Madhukar Pai (2011). “Mismanagement of tuberculosis in India: Causes, consequences, and the way forward”. Hypothesis 9 (1): e7. doi:10.5779/hypothesis.v9i1.214. http://www.hypothesisjournal.com/?p=989. ^ Harries AD; Hargreaves NJ, Kumwenda J, Kwanjana1 JH, Salaniponi1 FM (2000). “Trials of anti-tuberculosis treatment in areas of high human immunodeficiency virus prevalence in sub-Saharan Africa”. Int J Tuberc Lung Dis 4 (11): 998–1001. PMID 11092710. http://www.ingentaconnect.com/content/iuatld/ijtld/2000/00000004/00000011/art00004;jsessionid=11rx2g0lf2orf.alexandra. ^ “Trials of anti-tuberculosis treatment as a diagnostic tool in smear-negative tuberculosis are of questionable benefit”. Int J Tuberc Lung Dis 4 (11): 997. (2000). PMID 11092709. ^ WHO. The role of surgery in the treatment of pulmonary TB and multidrug- and extensively drug-resistant TB. WHO: Geneva 2014. p.8 ^ A.P. Naef (December 2003). “The mid-century revolution in thoracic and cardiovascular surgery: Part 2. Prelude to 20th century cardio-thoracic surgery”. Interactive Cardiovascular and Thoracic Surgery 2 (4): 431?449. doi:10.1016/S1569-9293(03)00190-7. http://icvts.oxfordjournals.org/content/2/4/431.full. ^ “Treatment and outcome analysis of 205 patients with multidrug-resistant tuberculosis”. Am J Respir Crit Care Med 169 (10): 1103–09. (2004). doi:10.1164/rccm.200308-1159OC. PMID 14742301. ^ “Pulmonary resection as an adjunct in the treatment of multiple drug-resistant tuberculosis”. Ann Thorac Surg 63 (5): 1368?72. (1997). doi:10.1016/s0003-4975(97)80353-0. PMID 9146329. ^ “Surgery increased the chance of cure in multi-drug resistant pulmonary tuberculosis”. Eur J Cardiothorac Surg 16 (2): 187–93. (1999). doi:10.1016/S1010-7940(99)00158-X. PMID 10485419. ^ a b “Pulmonary resection for multi-drug resistant tuberculosis”. J Thorac Cardiovasc Surg 121 (3): 448–53. (2001). doi:10.1067/mtc.2001.112339. PMID 11241079. ^ “A retrospective study for the outcome of pulmonary resection in 49 patients with multidrug-resistant tuberculosis”. Int J Tuberc Lung Dis 6 (2): 143–49. (2002). PMID 11931413. ^ “Lung resection for multidrug-resistant tuberculosis”. Asian Cardiovasc Thorac Ann 13 (2): 172–74. (2005). doi:10.1177/021849230501300216. PMID 15905349. ^ “Resectional surgery combined with chemotherapy remains the treatment of choice for multidrug-resistant tuberculosis”. J Thorac Cardiovasc Surg 128 (4): 523–28. (2004). doi:10.1016/j.jtcvs.2004.06.012. PMID 15457152. ^ a b “Surgical treatment of multi-drug resistant pulmonary tuberculosis in 188 cases 耐多藥肺結核188例的外科治療” (Chinese). Chinese Journal of Tuberculosis and Respiratory Diseases 中華結核和呼吸雜誌 29 (8): 524–26. (2006). PMID 17074264. オリジナルの2016-01-09時点におけるアーカイブ。. https://web.archive.org/web/20160109230152/http://cnki50.csis.com.tw/kns50/detail.aspx?QueryID=27&CurRec=9. ^ “Lobectomy or pneumonectomy for multidrug-resistant pulmonary tuberculosis can be performed with acceptable morbidity and mortality: A seven-year review of a single institution's experience”. J Thorac Cardiovasc Surg 134 (1): 194?98. (2007). doi:10.1016/j.jtcvs.2007.03.022. PMID 17599508. ^ “The relationship between malnutrition and tuberculosis: evidence from studies in humans and experimental animals”. Int J Tubercul Lung Dis 8 (3): 286–98. (2004). ^ Onwubalili JK. (1988). “Malnutrition among tuberculosis patients in Harrow, England”. Eur J Clin Nutr. 42 (4): 363–66. PMID 3396528. ^ “Poor Micronutrient Status of Active Pulmonary Tuberculosis Patients in Indonesia”. Journal of Nutrition 130: 2953–58. (2000). doi:10.1093/jn/130.12.2953. ^ “Moderate to severe malnutrition in patients with tuberculosis is a risk factor associated with early death”. Trans R Soc Trop Med Hyg. 96 (3): 291–94. (2002). doi:10.1016/S0035-9203(02)90103-3. PMID 12174782. ^ Baldwin M; Yori, PP; Ford, C; Moore, DA; Gilman, RH; Vidal, C; Ticona, E; Evans, CA (2004). “Tuberculosis and nutrition: disease perceptions and health seeking behavior of household contacts in the Peruvian Amazon”. Int J Tuberc Lung Dis 8 (12): 1484?91. PMC 2912521. PMID 15636496. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2912521/. ^ Sinclair, D; Abba, K; Grobler, L; Sudarsanam, TD (9 November 2011). “Nutritional supplements for people being treated for active tuberculosis.”. The Cochrane Database of Systematic Reviews (11): CD006086. doi:10.1002/14651858.CD006086.pub3. PMC 4981643. PMID 22071828. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4981643/. ^ “Low serum vitamin D levels and tuberculosis: a systematic review and meta-analysis”. Int J Epidemiol 37 (1): 113?19. (2008). doi:10.1093/ije/dym247. PMID 18245055. ^ Davies PD (1985). “A possible link between vitamin D deficiency and impaired host defence to Mycobacterium tuberculosis”. Tubercle 66 (4): 301–06. doi:10.1016/0041-3879(85)90068-6. PMID 3936248. ^ Vieth R (2011). “Vitamin D nutrient to treat TB begs the prevention question”. Lancet 377 (9761): 189, 190. doi:10.1016/S0140-6736(10)62300-8. PMID 21215444. ^ a b “Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response”. Science 311 (5768): 1770–73. (2006). doi:10.1126/science.1123933. PMID 16497887. ^ Finsen NR (1886). Om anvendelse i medicinen af koncentrerede kemiske lysstraaler. Copenhagen, Denmark: Gyldendalske Boghandels Forlag ^ “Effect of isoniazid on vitamin D metabolism and hepatic monooxygenase activity”. Clin Pharmacol Ther 30 (3): 363–67. (1981). doi:10.1038/clpt.1981.173. PMID 7273600. ^ “Effect of rifampicin and isoniazid on vitamin D metabolism”. Clin Pharmacol Ther 32 (4): 525–30. (1982). doi:10.1038/clpt.1982.197. PMID 7116768. ^ “Calcium metabolism during rifampicin and isoniazid therapy for tuberculosis”. J R Soc Med 75 (7): 533?36. (1982). PMC 1437875. PMID 7086805. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1437875/. ^ “Long term study of the effect of rifampicin and isoniazid on vitamin D metabolism”. Tubercle 66 (1): 49–54. (1985). doi:10.1016/0041-3879(85)90053-4. PMID 3838603. ^ Chan TY (1996). “Osteomalacia during rifampicin and isoniazid therapy is rare in Hong Kong”. Int J Clin Pharmacol Ther 34 (12): 533?34. PMID 8996847. ^ “Tuberculosis and chronic hepatitis B virus infection in africans and variation in the vitamin D receptor gene”. J Infect Dis 179 (3): 721–24. (1998). doi:10.1086/314614. PMID 9952386. ^ “Influence of vitamin D deficiency and vitamin D receptor polymorphisms on tuberculosis among Gujarati Asians in west London: a case-control study”. Lancet 355 (9204): 618–21. (2000). doi:10.1016/S0140-6736(99)02301-6. PMID 10696983. ^ ??,?翠英,??明 (2003). “?生素D受体基因多?性与肺?核易感性的病例?照研究 (A case-control study on the vitamin D receptor gene polymorphisms and susceptibility to pulmonary tuberclosis)” (Chinese). 中?流行病学?志 (Chinese Journal of Epidemiology) 24 (5): 389–92. PMID 12820934. ^ “High-dose vitamin D3 during intensive-phase antimicrobial treatment of pulmonary tuberculosis: a double-blind randomised controlled trial”. Lancet 377 (9761): 242?50. (2011). doi:10.1016/S0140-6736(10)61889-2. PMID 21215445. ^ “Adjunctive vitamin D for treatment of active tuberculosis in India: a randomised, double-blind, placebo-controlled trial.”. Lancet Infect Dis 15: 528?34. (2015). doi:10.1016/S1473-3099(15)70053-8. PMID 25863562. ^ “Vitamin D as supplementary treatment for tuberculosis: a double-blind, randomized, placebo-controlled trial”. Am J Respir Crit Care Med 179 (9): 843–50. (2009). doi:10.1164/rccm.200804-567OC. PMID 19179490. ^ “Tuberculosis and vitamin D: what's the rest of the story?”. Lancet Infect Dis 15: 489?90. (2015). doi:10.1016/S1473-3099(15)70163-5. PMC 4696485. PMID 25863560. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4696485/. ^ Williams, C. J. B. (1849). “Cod liver oil in phthisis”. London J Med 1: 1–18. doi:10.1136/bmj.s2-1.1.1. ^ Spector SA (2009). “Vitamin D earns more than a passing grade”. J Infect Dis 200 (7): 1015–17. doi:10.1086/605723. PMID 19673648. ^ “A single dose of vitamin D enhances immunity to Mycobacteria”. Am J Respir Crit Care Med 176 (2): 208?13. (2007). doi:10.1164/rccm.200701-007OC. PMID 17463418. ^ “Vitamin D3, gamma interferon, and control of proliferation of Mycobacterium tuberculosis by human monocytes”. Immunology 57 (1): 159–63. (1986). PMC 1453883. PMID 3002968. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1453883/. ^ “Inhibition by 1,25(OH)2-vitamin D3 of the multiplication of virulent tubercle bacilli in cultured human macrophages”. Infection and Immunity 55 (12): 2945–50. (1987). PMC 260011. PMID 3119492. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC260011/. ^ “1α,25-dihydroxyvitamin D3-induced monocyte antimycobacterial activity is regulated by phosphatidylinositol 3-kinase and mediated by the NADPH-dependent phagocyte oxidase”. J Biol Chem 276 (38): 35482–93. (2001). doi:10.1074/jbc.M102876200. PMID 11461902. ^ “IFN-γ- and TNF-independent vitamin D-inducible human suppression of mycobacteria: The role of cathelicidin LL-37”. Journal of Immunology 178: 7190–98. (2007). doi:10.4049/jimmunol.178.11.7190. ^ “1α,25-dihydroxyvitamin D3 inhibits matrix metalloproteinases induced by Mycobacterium tuberculosis infection”. Immunology 127 (4): 539–48. (2009). doi:10.1111/j.1365-2567.2008.03024.x. PMC 2729531. PMID 19178594. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2729531/. ^ “Weekly Rifapentine/Isoniazid or Daily Rifampin/Pyrazinamide for Latent Tuberculosis in Household Contacts”. Am J Respir Crit Care Med 173 (8): 922–26. (2006). doi:10.1164/rccm.200512-1953OC. PMC 2662911. PMID 16474028. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2662911/. ^ “Severe of fatal liver injury in 50 patients in the United States taking rifampin and pyrazinamide for latent tuberculosis”. Clin Infect Dis 42 (3): 346–55. (2006). doi:10.1086/499244. PMID 16392079. ^ Smieja M. J.; Marchetti C. A.; Cook D. J.; Smaill F. M. (2000). “Isoniazid for preventing tuberculosis in non-HIV infected persons”. Cochrane Database of Systematic Reviews 2: CD001363. doi:10.1002/14651858.CD001363. PMID 10796642. ^ “Rifamycins (rifampicin, rifabutin and rifapentine) compared to isoniazid for preventing tuberculosis in HIV-negative people at risk of active TB”. Cochrane Database Syst Rev 7: CD007545. (2013). doi:10.1002/14651858.CD007545.pub2. PMID 23828580. ^ “Treatment of Latent Tuberculosis Infection: A Network Meta-analysis”. Ann. Intern. Med. 161 (6): 419?28. (August 2014). doi:10.7326/M14-1019. PMID 25111745. http://annals.org/article.aspx?articleID=1895308. ^ “Moxifloxacin-containing regimen greatly reduces time to culture conversion in murine Tuberculosis”. Am J Respir Crit Care Med 169 (3): 421–26. (2004). doi:10.1164/rccm.200310-1380OC. PMID 14578218. ^ “The bactericidal activity of moxifloxacin in patients with pulmonary tuberculosis”. Am J Respir Crit Care Med 168 (11): 1342–45. (2003). doi:10.1164/rccm.200305-682OC. PMID 12917230. ^ “Moxifloxacin-containing regimens of reduced duration produce a stable cure in murine tuberculosis”. Am J Respir Crit Care Med 170 (10): 1131–34. (2004). doi:10.1164/rccm.200407-885OC. PMID 15306535. ^ TB Alliance. “TB Alliance and Bayer launch historic global TB drug trials”. 2006年9月25日時点のオリジナルよりアーカイブ。2006年10月17日閲覧。 Lienhardta C, Vernonb A, Raviglionec MC (2010). “New drugs and new regimens for the treatment of tuberculosis: review of the drug development pipeline and implications for national programmes” (PDF). Current Opinion in Pulmonary Medicine 16: 186?93. http://www.stoptb.org/assets/documents/research/COPM%20paper%20April%202010.pdf. 表 話 編 歴 薬理学：医薬品の分類 消化器/代謝（A）胃酸中和剤制酸薬 H2ブロッカー プロトンポンプ阻害薬 制吐薬 瀉下薬 止瀉薬/止痢薬 抗肥満薬 血糖降下薬 ビタミン ミネラル 血液、血液生成器官（B）抗血栓薬 抗血小板剤 抗凝固薬 血栓溶解薬 抗出血薬 血小板 凝固・線溶系 抗線維素溶解性 循環器系（C）心臓療法/狭心症治療薬 強心配糖体 抗不整脈薬 強心剤 高血圧治療薬 利尿薬 血管拡張薬 交感神経β受容体遮断薬 カルシウム拮抗剤 レニン・アンジオテンシン・アルドステロン系 ACE阻害薬 ARB レニン阻害薬 脂質降下薬 スタチン フィブラート 胆汁酸捕捉因子 皮膚（D）皮膚軟化剤 瘢痕形成剤 鎮痒薬 乾癬治療薬 他の皮膚薬 泌尿生殖器系（G）ホルモン避妊薬 排卵誘発治療 SERM 性ホルモン 内分泌器（H）視床下部脳下垂体ホルモン 副腎皮質ホルモン 鉱質コルチコイド 糖質コルチコイド 性ホルモン 甲状腺ホルモン/抗甲状腺薬 感染（J、P、QI）抗菌薬 抗生物質 抗真菌薬 抗ウイルス薬 抗寄生虫薬 抗原虫薬 駆虫薬 外部寄生虫駆除剤 静注用免疫グロブリン ワクチン 悪性腫瘍（L01-L02）抗がん剤 代謝拮抗薬 抗腫瘍性アルキル化薬 紡錘体毒 抗悪性腫瘍薬 トポイソメラーゼ阻害薬 免疫系（L03-L04）免疫調節薬免疫賦活薬 免疫抑制剤 筋肉、骨、関節（M）アナボリックステロイド 抗炎症薬 (NSAIDs) 抗リウマチ 副腎皮質ホルモン 筋弛緩剤 ビスホスホネート 脳、神経（N）鎮痛剤 麻酔剤 一般 局所 静脈 食欲低下薬 ADHD治療 中毒医学 抗てんかん薬 アルツハイマー治療 抗うつ薬 片頭痛治療 抗パーキンソン病薬 抗精神病薬 抗不安薬 抑制剤 エンタクトゲン エンセオジェン 陶酔薬 幻覚剤 サイケデリック 解離性麻酔薬 デリリアント 催眠薬/鎮静薬 気分安定薬 神経保護 スマートドラッグ 神経毒 食欲促進 セレニック 精神刺激薬 覚醒促進物質 呼吸器（R）充血除去薬 気管支拡張薬 鎮咳去痰薬 抗ヒスタミン薬 感覚器（S）眼科学 耳鼻咽喉科学 その他ATC（V）解毒剤 造影剤 放射性薬理学 湿潤療法